Wells Fargo’s Acurx Pharmaceuticals ACXP Stock Holding History

Wells Fargo’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.56K	Hold	2,300	–	–	﹤0.01%	6286
2026 Q1	$8.53K	Hold	2,300	–	–	﹤0.01%	5998
2025 Q4	$5.73K	Buy	+2,300	New	+$11K	﹤0.01%	6064
2024 Q2	–	Sell	-4	Closed	-$213	–	6867
2024 Q1	$213	Hold	4	–	–	﹤0.01%	6485
2023 Q4	$310	Hold	4	–	–	﹤0.01%	6495
2023 Q3	$116	Buy	4 +1	+33%	+$38	﹤0.01%	6730
2023 Q2	$172	Hold	3	–	–	﹤0.01%	6742
2023 Q1	$215	Hold	3	–	–	﹤0.01%	6757
2022 Q4	$243	Hold	3	–	–	﹤0.01%	6566
2022 Q3	$0	Buy	3 +2	+200%	+$150	﹤0.01%	6587
2022 Q2	$0	Hold	1	–	–	﹤0.01%	6736
2022 Q1	$0	Hold	1	–	–	﹤0.01%	6973
2021 Q4	$0	Hold	1	–	–	﹤0.01%	7165
2021 Q3	$0	Buy	+1	New	+$103	﹤0.01%	6913

Other funds holding ACXP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Wells Fargo's ACXP Position: Q2 2026 in Review

Wells Fargo held its Acurx Pharmaceuticals (ACXP) position steady in Q2 2026 at 2,300 shares worth $3.56K. The position accounts for ﹤0.01% of the portfolio, ranked #6286.

Wells Fargo first reported a position in ACXP in Q3 2021 and has held it in 14 quarters since. The position peaked at $8.53K in Q1 2026. 18 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

Wells Fargo held 2,300 shares of Acurx Pharmaceuticals worth $3.56K as of Q2 2026.
Wells Fargo left its Acurx Pharmaceuticals share count unchanged in Q2 2026.
Acurx Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6286 holding.
Wells Fargo first reported a position in Acurx Pharmaceuticals in Q3 2021 and has held it in 14 quarters since.
Wells Fargo's Acurx Pharmaceuticals position peaked at $8.53K in Q1 2026.
18 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.